Tolvaptan in a pediatric patient with diuretic-resistant heart and kidney failure

Pediatrics International

Volumn 57, Issue 1, 2015, Pages 183-185

  Hirano, Daishi ^a   Kakegawa, Daisuke ^a   Yamada, Akifumi ^a   Ito, Akira ^a   Miwa, Saori ^a   Ida, Hiroyuki ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

children; chronic kidney disease; congestive heart failure; furosemide; tolvaptan

Indexed keywords

FUROSEMIDE; SPIRONOLACTONE; TOLVAPTAN; BENZAZEPINE DERIVATIVE; DIURETIC AGENT; VASOPRESSIN RECEPTOR ANTAGONIST;

ARTICLE; CASE REPORT; CHILD; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; GENERALIZED EDEMA; HEART EJECTION FRACTION; HEART FUNCTION; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MALE; OLIGURIA; PRIORITY JOURNAL; PROTEINURIA; SCHOOL CHILD; URINALYSIS; COMPLICATION; DRUG RESISTANCE; HEART FAILURE; RENAL INSUFFICIENCY;

ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; CHILD; DIURETICS; DRUG RESISTANCE; HEART FAILURE; HUMANS; MALE; RENAL INSUFFICIENCY;

EID: 84923351643     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/ped.12590     Document Type: Article

References (10)

1. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343.
2. Schrier RW, Gross P, Gheorghiade M, et al.; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 2006; 16: 2099-2112.
3. Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S,. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin. Exp. Nephrol. 2013; 17: 834-838.
4. Nishizaki Y, Yamagami S, Sesoko M, Yamashita H, Daida H,. Successful treatment of congestive heart failure with concomitant administration of tolvaptan to enhance the effects of furosemide. J. Cardiol. Cases 2013; 8: 151-154.
5. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 2003; 42: 705-708.
6. Ellison DH,. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001; 96: 132-143.
7. Loon NR, Wilcox CS, Unwin RJ,. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989; 36: 682-689.
8. Kaissling B, Bachmann S, Kriz W,. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am. J. Physiol. 1985; 248: F374-F381.
9. Shin DD, Brandimarte F, De Luca L, et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am. J. Cardiol. 2007; 99: 4A-23A.
10. Shoaf SE, Bricmont P, Mallikaarjun S,. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int. 2014; 85: 953-961.